Reis–Bucklers corneal dystrophy

From WikiMD's Medical Encyclopedia

Revision as of 14:33, 9 April 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Reis–Bücklers corneal dystrophy
Reticular opacity in the superficial cornea
Synonyms Corneal dystrophy of Bowman layer, type I
Pronounce N/A
Specialty N/A
Symptoms Corneal opacity, visual impairment
Complications N/A
Onset Childhood
Duration Progressive
Types N/A
Causes Genetic mutation in the TGFB1 gene
Risks Family history
Diagnosis Slit-lamp examination, genetic testing
Differential diagnosis Granular corneal dystrophy, Lattice corneal dystrophy
Prevention N/A
Treatment Phototherapeutic keratectomy, corneal transplant
Medication N/A
Prognosis Variable, may lead to significant visual impairment
Frequency Rare
Deaths None directly


Mutated transforming growth factor beta induced protein in the superficial corneal stroma

Reis–Bucklers corneal dystrophy (RBCD) is a rare, autosomal dominant genetic disorder affecting the cornea. It is characterized by the development of bilateral, symmetric, reticular opacities in the cornea, leading to recurrent corneal erosions, pain, and eventually, a decrease in visual acuity. This condition is classified under the broader category of corneal dystrophies, which are a group of inherited eye disorders where abnormal material accumulates in the cornea, the clear outer layer of the eye.

Etiology and Genetics[edit]

RBCD is caused by mutations in the TGFBI gene, which encodes for transforming growth factor-beta-induced protein. This protein plays a crucial role in the development, maintenance, and repair of the cornea. Mutations in the TGFBI gene lead to the production of abnormal protein, which accumulates in the cornea and disrupts its normal architecture and function. Being an autosomal dominant disorder, a single copy of the mutated gene inherited from an affected parent is sufficient to cause the disease.

Clinical Features[edit]

The onset of RBCD typically occurs in the first or second decade of life. Early symptoms include episodes of pain, tearing, and sensitivity to light due to recurrent corneal erosions. Over time, the erosions lead to the development of characteristic reticular (net-like) opacities in the cornea, which can significantly impair vision. The severity of visual impairment varies among individuals and can progress to significant vision loss.

Diagnosis[edit]

Diagnosis of RBCD is primarily based on clinical examination, including a detailed patient history and slit-lamp examination of the cornea. The distinctive appearance of the corneal opacities usually allows for a straightforward diagnosis. Genetic testing can confirm the diagnosis by identifying mutations in the TGFBI gene.

Treatment[edit]

Treatment of RBCD focuses on managing symptoms and preventing progression of the disease. In the early stages, lubricating eye drops and ointments can be used to alleviate discomfort from corneal erosions. In more severe cases, or when vision is significantly affected, surgical options may be considered. These can include phototherapeutic keratectomy (PTK), which uses laser technology to remove the abnormal corneal tissue, or corneal transplantation in cases where the cornea is extensively damaged.

Prognosis[edit]

The prognosis for individuals with RBCD varies. While the condition can significantly affect quality of life due to recurrent pain and vision loss, advances in treatment, especially surgical interventions, have improved outcomes. Early diagnosis and management are crucial in preserving vision and reducing the impact of the disease.

Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.